It appears as though the link broke in yesterday’s RSS feed for the Boulder Biotechnology Company Tree .pdf. Here is the link: http://ab.rubenstein.googlepages.com/boulderbiotechtreeoct07 My apologies for any frustrations and a hearty thank you to the ever vigilant wonder-attorney Jeff Bojar, JD, MS of Snell & Wilmer who pointed out the error to me. This provides [...]

• 354http://clsdf.com/2008/03/update-boulder-biotechnology-company-tree/UPDATE%3A+Boulder+Biotechnology+Company+Tree2008-03-25+15%3A28%3A00admin

It’s a GlobeImmune kind of day…How exciting to see Dr. Freytag join the GI Board of Directors. Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Aspreva Pharmaceuticals Company from July 2007 through December 2007 when Aspreva was acquired by Galenica for approximately $915 million. He held the same positions with [...]

• 353http://clsdf.com/2008/03/j-william-freytag-ph-d-appointed-to-globeimmune-board/J.+William+Freytag%2C+Ph.D.+Appointed+to+GlobeImmune+Board2008-03-25+15%3A20%3A00admin

GlobeImmune initiated a Phase IIa trial to evaluate their GI-4000 Tarmogen® for the treatment of non-small cell lung cancer (NSCLC) patients with tumors having mutations in the ras gene. NSCLC patients with tumors positive for mutated ras may have a worse survival compared to patients with other NSCLC types and therefore these patients may not [...]

• 352http://clsdf.com/2008/03/globeimmune-initiates-phase-iia-gi-4000-nsclc-study/GlobeImmune+Initiates+Phase+IIa+GI-4000+NSCLC+Study2008-03-25+15%3A13%3A00admin